Loading the section
Closing prices for 09 October 2026
Next earnings report: 02 November 2026 · Earnings calendar
The series is stated in the current share scale after splits; dividends are not included in the price
TG Therapeutics, Inc. trades on Nasdaq under the ticker TGTX. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks TGTX has traded between 26.76 $ and 59.30 $. As of 09 October 2026 the price stood 87.92 % of the way from the 52-week low to the high.
Over one year TGTX shares rose 54.88 %; over six months they rose 64.16 %. Volatility over 90 days is 47.11 %. Dividends are not included: this is price change only, as of 09 October 2026.
TGTX trades at a price-to-earnings ratio of 17.8, below the sector median of 24.8. Price to sales is 11.7, above the sector median of 3.9. Price to book is 14.1, above the sector median of 2.4. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 09 October 2026 | 53.72 | 55.46 | 53.36 | 55.37 | 2M |
| 08 October 2026 | 53.34 | 53.90 | 52.12 | 53.34 | 2M |
| 07 October 2026 | 51.83 | 53.88 | 51.41 | 52.95 | 2M |
| 06 October 2026 | 54.11 | 54.11 |
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
TG Therapeutics, Inc. (TGTX) is a public company in the healthcare sector. Its common stock trade on NASDAQ.
Over the trailing twelve months as reported to 2025-12-31, revenue was 616.3m $, net income was 447.2m $. Incorporated in US.
This summary is compiled automatically from SEC filings and exchange data.
Address:2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY, 10014, US
TG Therapeutics, Inc. reported revenue of 700M $ and net income of 462M $ over the last four quarters. Net margin is 65.95 %. Revenue changed by +81.26 % year over year. Earnings per share are 2.86 $. Market capitalisation is 8.2B $.
TGTX has a return on equity of 79.21 %, above the sector median of −41.68 %. Return on assets is 30.21 %, above the sector median of −32.11 %. Operating margin is 21.35 %, above the sector median of −26.84 %.
| 1.2B |
| PFEPfizer, Inc. | 28.18 | +1.28 % | 929M |
| ABTAbbott Laboratories | 99.60 | +1.13 % | 921M |
| BMYBristol-Myers Squibb Company | 59.12 | −0.77 % | 714M |
| REGNRegeneron Pharmaceuticals, Inc. | 746.54 | +0.94 % | 555M |
| 51.34 |
| 52.19 |
| 2M |
| 05 October 2026 | 54.35 | 54.75 | 53.32 | 53.91 | 2M |
| 02 October 2026 | 54.17 | 54.98 | 53.15 | 54.29 | 2M |
| 01 October 2026 | 55.58 | 56.12 | 53.59 | 53.62 | 2M |
| 30 September 2026 | 56.41 | 56.98 | 55.36 | 55.78 | 2M |
| 29 September 2026 | 56.04 | 56.68 | 54.79 | 56.19 | 2M |
| 28 September 2026 | 57.35 | 57.66 | 55.88 | 56.19 | 1M |
| 25 September 2026 | 57.97 | 58.69 | 56.61 | 57.43 | 1M |
| 24 September 2026 | 55.95 | 57.55 | 55.09 | 57.52 | 1M |
| 23 September 2026 | 58.11 | 58.25 | 54.78 | 56.00 | 2M |
| 22 September 2026 | 57.41 | 58.62 | 56.56 | 58.11 | 2M |
| 21 September 2026 | 57.23 | 58.92 | 56.00 | 57.16 | 2M |
| 18 September 2026 | 56.98 | 57.73 | 56.18 | 56.87 | 5M |
| 17 September 2026 | 57.61 | 57.87 | 56.04 | 56.47 | 1M |
| 16 September 2026 | 53.12 | 57.61 | 53.11 | 55.85 | 2M |
| 15 September 2026 | 53.59 | 54.41 | 52.50 | 53.04 | 2M |
| 14 September 2026 | 53.97 | 54.20 | 53.19 | 54.00 | 1M |